Objective: To analyze whether the use of an intermittent (IAD) versus continuous (CAD) androgen deprivation therapy for the treatment of biochemical progression after primary treatments (radical prostatectomy and radiation therapy) in hormone sensitive non-metastatic prostate cancer can influence the development of non-metastatic castration resistant prostate cancer (CRPC-M0) .
INTERMITTENT VERSUS CONTINUOUS ANDROGEN DEPRIVATION THERAPY FOR BIOCHEMICAL PROGRESSION AFTER PRIMARY THERAPY IN HORMONE-SENSITIVE NON-METASTATIC PROSTATE CANCER: COMPARATIVE ANALYSIS IN TERMS OF CRPC-M0 PROGRESSION / Salciccia, Stefano; Frisenda, Marco; Tufano, Antonio; Pierro, Giovanni Di; Bevilacqua, Giulio; Rosati, Davide; Gobbi, Luca; Basile, Greta; Moriconi, Martina; Mariotti, Gianna; Forte, Flavio; Carbone, Antonio; Pastore, Antonio; Cattarino, Susanna; Sciarra, Alessandro; Gentilucci, Alessandro. - In: CLINICAL GENITOURINARY CANCER. - ISSN 1558-7673. - (2023). [10.1016/j.clgc.2023.08.008]
INTERMITTENT VERSUS CONTINUOUS ANDROGEN DEPRIVATION THERAPY FOR BIOCHEMICAL PROGRESSION AFTER PRIMARY THERAPY IN HORMONE-SENSITIVE NON-METASTATIC PROSTATE CANCER: COMPARATIVE ANALYSIS IN TERMS OF CRPC-M0 PROGRESSION
Salciccia, Stefano;Frisenda, Marco;Tufano, Antonio;Pierro, Giovanni Di;Bevilacqua, Giulio;Gobbi, Luca;Basile, Greta;Moriconi, Martina;Forte, Flavio;Pastore, Antonio;Cattarino, Susanna;Sciarra, Alessandro;Gentilucci, Alessandro
2023
Abstract
Objective: To analyze whether the use of an intermittent (IAD) versus continuous (CAD) androgen deprivation therapy for the treatment of biochemical progression after primary treatments (radical prostatectomy and radiation therapy) in hormone sensitive non-metastatic prostate cancer can influence the development of non-metastatic castration resistant prostate cancer (CRPC-M0) .I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
